Our top pick for
Beginners

NantKwest Inc is a biotechnology business based in the US. NantKwest shares (NK) are listed on the NASDAQ and all prices are listed in US Dollars. NantKwest employs 171 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
Latest market close | $0.00 |
---|---|
52-week range | $33.64 - $40.90 |
50-day moving average | $28.70 |
200-day moving average | $14.19 |
Wall St. target price | $18.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.89 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0 from 2022-01-14
1 week (2022-06-19) | nan% |
---|---|
1 month (2022-05-26) | nan% |
3 months (2022-03-26) | nan% |
6 months (2021-12-26) | nan% |
1 year (2021-06-30) | -100.00% |
---|---|
2 years (2020-06-30) | -100.00% |
3 years (2019-06-28) | 1.02 |
5 years (2017-06-30) | 7.59 |
Valuing NantKwest stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NantKwest's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
NantKwest's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.56. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NantKwest's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Revenue TTM | $111,000 |
---|---|
Gross profit TTM | $111,000 |
Return on assets TTM | -36.2% |
Return on equity TTM | -77.61% |
Profit margin | 0% |
Book value | $1.08 |
Market capitalisation | $3.6 billion |
TTM: trailing 12 months
We're not expecting NantKwest to pay a dividend over the next 12 months.
NantKwest's shares were split on a 8:1 basis on 16 August 2012. So if you had owned 1 share the day before before the split, the next day you'd have owned 8 shares. This wouldn't directly have changed the overall worth of your NantKwest shares – just the quantity. However, indirectly, the new 87.5% lower share price could have impacted the market appetite for NantKwest shares which in turn could have impacted NantKwest's share price.
Over the last 12 months, NantKwest's shares have ranged in value from as little as $33.64 up to $40.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NantKwest's is 2.3862. This would suggest that NantKwest's shares are significantly more volatile than the average for this exchange and represent a higher risk.
NantKwest, Inc. , a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.